PRNewsWire
22 Sept 2025, 12:05 UTC · 52w ago
Verdict
Headline takes no side. We score ANIX +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Anixa Biosciences will present the final results of its Phase 1 breast cancer vaccine clinical trial at the San Antonio Breast Cancer Symposium on December 11, 2025.
More positive than 92% of claims this week
The company's CEO stated that the human clinical trial data has continued to exceed expectations.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 76% of claims this week
Anixa intends to use the trial results to inform discussions with the FDA and advance plans for Phase 2 development.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
The company is announcing the presentation of Phase 1 clinical trial results that have 'exceeded expectations' for its breast cancer vaccine.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−17.3%
Price is moving against the score
$2.73 vs $3.30 close before publication (Sep 19) · not market-adjusted
ANIX chart →
